{
  "schemaVersion": 2,
  "eyebrow": "Endocrinology",
  "title": "Osteoporosis in Females",
  "summary": "A fracture-focused approach to osteoporosis in postmenopausal females: establish treatment eligibility from fragility fracture, DXA, and FRAX; exclude remediable secondary causes; select antiresorptive or bone-forming therapy by fracture risk; and prevent treatment gaps that accelerate bone loss.",
  "seoDescription": "Point-of-care management of osteoporosis in females: DXA and FRAX thresholds, secondary workup, drug selection, sequencing, and monitoring.",
  "clinicalQuestion": "How should clinicians evaluate, risk-stratify, treat, and monitor osteoporosis in postmenopausal females?",
  "specialty": "Endocrinology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "postmenopausal osteoporosis",
    "DXA",
    "FRAX",
    "bisphosphonates",
    "denosumab",
    "romosozumab",
    "teriparatide",
    "fragility fracture"
  ],
  "keyTakeaways": [
    "Treat a hip or vertebral fracture regardless of BMD; a DXA T-score of -2.5 or lower also supports pharmacotherapy. [19][20]",
    "For osteopenia, use US-adapted FRAX: treat when 10-year hip-fracture risk is at least 3% or major osteoporotic-fracture risk is at least 20%. [19][20]",
    "Bisphosphonates are the ACP-recommended initial pharmacologic treatment for primary osteoporosis; denosumab is a second-line option when bisphosphonates are contraindicated or not tolerated. [21]",
    "Do not stop denosumab without follow-on bisphosphonate therapy; discontinuation is associated with rapid bone loss and increased vertebral-fracture risk. [9][13]",
    "For females at very high fracture risk, consider romosozumab or recombinant PTH therapy followed by a bisphosphonate rather than leaving an anabolic course unsequenced. [23]"
  ],
  "sections": [
    {
      "id": "identify-treatment-eligible-patients",
      "eyebrow": "Risk classification",
      "heading": "Identify females who need pharmacologic treatment",
      "intro": "Base treatment on prior fragility fracture, DXA category, and absolute fracture probability.",
      "paragraphs": [
        "Obtain central DXA and interpret T-scores in postmenopausal women. Initiate pharmacotherapy for a hip or vertebral fracture, whether clinically recognized or identified on vertebral imaging, regardless of BMD. A T-score of -2.5 or lower at the femoral neck, total hip, lumbar spine, or 33% radius also supports treatment. [2][20]",
        "For a postmenopausal woman with osteopenia, defined as a T-score between -1.0 and -2.5, calculate US-adapted FRAX using femoral-neck or total-hip BMD when available. A 10-year hip-fracture probability of 3% or greater or major osteoporotic-fracture probability of 20% or greater meets a commonly used treatment threshold. [19][20]",
        "A proximal humerus, pelvis, or distal forearm fracture in a patient with osteopenia favors treatment; if BMD is not low, individualize according to the fracture mechanism and global risk profile. Reassess fracture risk after every incident fracture because a fracture on or off therapy changes treatment intensity and prompts evaluation for contributors to skeletal fragility. [20][22]"
      ],
      "bullets": [
        "Classify as very high risk when prior hip or spine fracture, multiple fractures, or other features indicate an urgent need for maximal fracture-risk reduction; this is the group in whom ACP supports bone-forming therapy followed by a bisphosphonate. [23]",
        "For low-risk patients without prior spine or hip fracture, with hip and spine T-scores above -1.0 and FRAX below treatment thresholds, reassess rather than prescribe medication. [20]"
      ],
      "subsections": [],
      "table": {
        "caption": "Treatment-entry criteria for postmenopausal females. [19][20]",
        "columns": [
          "Finding",
          "Clinical action"
        ],
        "rows": [
          [
            "Hip or vertebral fracture, including asymptomatic vertebral fracture on imaging",
            "Treat regardless of BMD. [19][20]"
          ],
          [
            "DXA T-score -2.5 or lower at femoral neck, total hip, lumbar spine, or 33% radius",
            "Offer pharmacotherapy after clinical assessment. [20]"
          ],
          [
            "Osteopenia at femoral neck or total hip plus FRAX hip risk at least 3%",
            "Offer pharmacotherapy. [19][20]"
          ],
          [
            "Osteopenia at femoral neck or total hip plus FRAX major osteoporotic-fracture risk at least 20%",
            "Offer pharmacotherapy. [19][20]"
          ],
          [
            "Proximal humerus, pelvis, or distal forearm fracture with osteopenia",
            "Favor treatment; individualize if BMD is normal. [20]"
          ]
        ]
      }
    },
    {
      "id": "evaluate-secondary-contributors",
      "eyebrow": "Diagnostic workup",
      "heading": "Evaluate secondary causes before labeling bone loss as primary",
      "intro": "Use fracture pattern, medication exposure, examination, and laboratory abnormalities to direct the workup.",
      "paragraphs": [
        "Before or concurrent with treatment, review for conditions and exposures that alter management: chronic kidney disease, hypercalcemia or hypocalcemia, vitamin D deficiency, hyperparathyroidism, malignancy, and medication-associated bone loss. Initial laboratory assessment can include CBC and serum calcium; abnormalities should trigger disease-directed testing rather than empiric escalation of osteoporosis therapy. [3]",
        "In chronic kidney disease, obtain DXA plus serum calcium, phosphorus, 25-hydroxyvitamin D, PTH, and kidney-independent bone-turnover markers. In advanced CKD, bone biopsy can directly define turnover, mineralization, and volume when renal osteodystrophy phenotype would alter therapy. [12]",
        "Distinguish routine postmenopausal osteoporosis from CKD-associated mineral and bone disorder before selecting potent antiresorptive treatment in CKD stages 4-5. Drug efficacy and safety data are limited in this population, and denosumab-associated hypocalcemia is a particular safety concern. [12]"
      ],
      "bullets": [
        "Investigate unexplained BMD decline during alendronate treatment for secondary bone loss and for treatment nonadherence before declaring pharmacologic failure. [5]",
        "Correct calcium and vitamin D deficits as part of pharmacologic management; guideline recommendations address calcium and vitamin D repletion alongside drug therapy. [8]"
      ],
      "subsections": [],
      "table": {
        "caption": "Workup branch for suspected secondary osteoporosis or CKD-associated bone disease. [3][12]",
        "columns": [
          "Clinical pattern",
          "Tests that redirect management",
          "Interpretation and next step"
        ],
        "rows": [
          [
            "Unexpected BMD loss while taking alendronate",
            "Review adherence and evaluate for secondary causes of bone loss. [5]",
            "Do not automatically switch therapy without identifying remediable causes. [5]"
          ],
          [
            "Low eGFR or suspected CKD-mineral and bone disorder",
            "DXA; calcium, phosphorus, 25-hydroxyvitamin D, PTH, and kidney-independent turnover markers. [12]",
            "Use biochemical phenotype to guide therapy; evidence is limited in CKD stages 4-5. [12]"
          ],
          [
            "Advanced CKD when turnover or mineralization status would change treatment",
            "Bone biopsy. [12]",
            "Biopsy directly assesses turnover, mineralization, and bone volume. [12]"
          ],
          [
            "CBC or serum calcium abnormality",
            "Targeted evaluation for malignancy or calcium-regulatory disorder. [3]",
            "Treat the identified disorder alongside fracture prevention. [3]"
          ]
        ]
      }
    },
    {
      "id": "select-initial-therapy",
      "eyebrow": "Pharmacotherapy",
      "heading": "Select therapy by fracture risk, tolerance, and need for an exit strategy",
      "intro": "Use an antiresorptive for most patients; reserve bone-forming treatment for very high fracture risk.",
      "paragraphs": [
        "For postmenopausal females with primary osteoporosis, ACP recommends a bisphosphonate as initial pharmacologic therapy to reduce fracture risk. Oral bisphosphonates are also identified as first-line treatment in broader osteoporosis guidance; intravenous zoledronate is an alternative when oral administration is not feasible or tolerated. [21][8]",
        "Use denosumab as second-line therapy for postmenopausal females with contraindications to or adverse effects from bisphosphonates. Before choosing denosumab, establish that the patient can receive on-time ongoing treatment and can transition to a bisphosphonate if it must be discontinued. [21][9][13]",
        "For females at very high fracture risk, ACP conditionally supports romosozumab or recombinant PTH therapy followed by a bisphosphonate. Sequential therapy is clinically important: BMD declines after romosozumab discontinuation, and an anabolic course should be followed by an antiresorptive agent rather than treated as a stand-alone intervention. [23][9][17]",
        "Match the agent to fracture goal. Alendronate has evidence for hip, vertebral, and nonvertebral fracture prevention; ibandronate has evidence for vertebral-fracture prevention but insufficient evidence for hip-fracture prevention. Raloxifene reduces vertebral but not hip or nonvertebral fracture incidence. [22]"
      ],
      "bullets": [
        "Avoid using treatment choice as a substitute for calcium and vitamin D repletion, physical activity, and a balanced diet. [8]",
        "In CKD stages 4-5, recognize that fracture-risk reduction has not been demonstrated for oral bisphosphonates or denosumab, while denosumab-related hypocalcemia constrains use. [12]",
        "Consider cardiovascular risk when choosing romosozumab; cardiovascular adverse reactions have been reported, although available evidence has not definitively established causality. [9]"
      ],
      "subsections": [],
      "table": {
        "caption": "Medication selection and sequencing in postmenopausal osteoporosis. [21][22][23]",
        "columns": [
          "Clinical situation",
          "Preferred approach",
          "Key limitation or follow-on action"
        ],
        "rows": [
          [
            "Primary osteoporosis requiring initial treatment",
            "Start a bisphosphonate. [21]",
            "Assess oral-treatment feasibility and adherence. [8]"
          ],
          [
            "Bisphosphonate contraindication or adverse effects",
            "Use denosumab as second-line treatment. [21]",
            "Plan bisphosphonate transition if denosumab is stopped. [13]"
          ],
          [
            "Very high fracture risk",
            "Use romosozumab or recombinant PTH, then a bisphosphonate. [23]",
            "Do not leave bone-forming therapy unsequenced. [9][17]"
          ],
          [
            "Need to reduce hip, vertebral, and nonvertebral fractures",
            "Prefer an agent with evidence across these outcomes, such as alendronate. [22]",
            "Ibandronate has insufficient evidence for hip-fracture prevention. [22]"
          ],
          [
            "Predominantly vertebral-fracture objective when other options are unsuitable",
            "Raloxifene or ibandronate may reduce vertebral fractures. [22]",
            "Neither has established hip-fracture benefit in this summary. [22]"
          ]
        ]
      }
    },
    {
      "id": "monitor-response-and-treatment-transitions",
      "eyebrow": "Follow-up",
      "heading": "Monitor adherence, fracture events, and medication discontinuation",
      "intro": "A new fracture, measurable BMD decline, or delayed denosumab dose requires a specific reassessment.",
      "paragraphs": [
        "Monitor oral bisphosphonate adherence actively because dosing complexity and adverse effects commonly undermine persistence. Bone-turnover markers can be measured at baseline and approximately 3 months; a decrease exceeding least significant change, reported as more than 38% for P1NP or more than 56% for CTX, can support adequate antiresorptive response and adherence. [8]",
        "Reassess fracture risk after 3-5 years of bisphosphonate treatment and after any new fracture. The decision to continue, pause, or change therapy should incorporate interval fracture, BMD trajectory, adherence, and secondary-cause evaluation rather than duration alone. [22]",
        "Do not stop denosumab without follow-on bisphosphonate therapy. Denosumab discontinuation is linked to rapid bone loss and increased vertebral-fracture risk, whereas follow-on bisphosphonate therapy is necessary to mitigate this rebound clinical problem. [9][13]",
        "Persistent or unexplained BMD loss during therapy should trigger confirmation of adherence and repeat assessment for secondary causes. In advanced CKD, reassess calcium and mineral-metabolism parameters before and during therapies with hypocalcemia risk. [5][12]"
      ],
      "bullets": [
        "Use P1NP and CTX only when results will affect an adherence or treatment-response decision; interpret change against the reported least-significant-change thresholds. [8]",
        "After a completed abaloparatide course, alendronate continuation has demonstrated an effective sequential treatment approach in postmenopausal women at fracture risk. [17]"
      ],
      "subsections": [],
      "table": {
        "caption": "Action triggers during osteoporosis treatment. [5][8][9][12][13][22]",
        "columns": [
          "Trigger",
          "Immediate action",
          "Why it matters"
        ],
        "rows": [
          [
            "Oral bisphosphonate use with uncertain adherence",
            "Review administration and persistence; consider baseline and 3-month P1NP or CTX. [8]",
            "A P1NP reduction greater than 38% or CTX reduction greater than 56% exceeds reported least significant change. [8]"
          ],
          [
            "New fracture on therapy",
            "Reassess fracture risk, adherence, and secondary causes. [5][22]",
            "A fracture changes risk category and may justify treatment intensification. [22]"
          ],
          [
            "BMD decline while taking alendronate",
            "Evaluate secondary causes and adherence. [5]",
            "Decline is not by itself proof of drug failure. [5]"
          ],
          [
            "Stopping denosumab",
            "Initiate follow-on bisphosphonate therapy. [13]",
            "Abrupt discontinuation is associated with rapid bone loss and increased vertebral-fracture risk. [9][13]"
          ],
          [
            "CKD stages 4-5",
            "Monitor calcium and CKD-mineral bone parameters; use drug therapy cautiously. [12]",
            "Evidence is limited and denosumab can cause clinically important hypocalcemia. [12]"
          ]
        ]
      }
    }
  ],
  "faq": [],
  "references": [
    {
      "number": 1,
      "title": "21-318 FORTEO Medical Review Part 1 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-318_FORTEO_Medr_P1.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 2,
      "title": "Osteoporosis | Annals of Internal Medicine",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/10.7326/AITC201708010",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org"
    },
    {
      "number": 3,
      "title": "Osteoporosis",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-155-1-201107050-01001",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org"
    },
    {
      "number": 4,
      "title": "Screening for Osteoporosis",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-153-2-201007200-00262",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org"
    },
    {
      "number": 5,
      "title": "How Would You Manage This Patient With Osteoporosis?",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/10.7326/M18-0950",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org"
    },
    {
      "number": 6,
      "title": "Development of a diverse osteoporosis screening tool for ...",
      "detail": "www.cell.com",
      "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(23)11014-0",
      "authors": "www.cell.com",
      "host": "www.cell.com"
    },
    {
      "number": 7,
      "title": "Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-024-73398-5",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 8,
      "title": "Evidence-Based Guideline for the management of ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41584-024-01094-9",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 9,
      "title": "Insights and implications of sexual dimorphism in osteoporosis | Bone Research",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41413-023-00306-4",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 10,
      "title": "Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-023-37944-x",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 11,
      "title": "Management of Postmenopausal Osteoporosis",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000004730~management-of-postmenopausal-osteoporosis-acog-clinical",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 12,
      "title": "Management of Osteoporosis and Low Bone Mass in Kidney ...",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cjasn/fulltext/10.2215/cjn.0000001149~management-of-osteoporosis-and-low-bone-mass-in-kidney",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 13,
      "title": "Postmenopausal osteoporosis",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/menopausejournal/_layouts/15/oaks.journals/downloadpdf.aspx?an=",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 14,
      "title": "Medical Management of Osteoporosis: Updates and Future ...",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/isoj/_layouts/15/oaks.journals/downloadpdf.aspx?an=",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 15,
      "title": "A Review of the Evidence and Suggested Guidelines for Its Use",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/edrv/article/26/5/688/2355192",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 16,
      "title": "The Challenges and Opportunities of ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jbmrplus/article-pdf/2/4/187/55120648/jbm410051.pdf",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 17,
      "title": "ACTIVExtend: 24 Months of Alendronate After 18 Months of ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jcem/article/103/8/2949/5001732",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 18,
      "title": "Denosumab After Teriparatide in Premenopausal Women ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jcem/article-pdf/107/4/e1528/43775497/dgab850.pdf",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 19,
      "title": "Clinician’s Guide to Prevention and Treatment of Osteoporosis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4176573",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "The clinician's guide to prevention and treatment of osteoporosis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9546973",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10885682",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "A Review of Various Clinical Practice Guidelines on Osteoporosis in the Last 5 Years",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10721745",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "Additional Background and Contextual Questions 2, 3, and 4 - Screening for Osteoporosis to Prevent Fractures: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK611362",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "Appendix A Table 4, Recommendations for Fracture or Osteoporosis Screening by Organization - Screening for Osteoporosis to Prevent Fractures: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK611362/table/appa.tab4",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "21-318 FORTEO Medical Review Part 1 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-318_FORTEO_Medr_P1.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "Forteo is indicated for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture to reduce their risk of",
      "score": 0.29988423
    },
    {
      "number": 2,
      "title": "Osteoporosis | Annals of Internal Medicine",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/10.7326/AITC201708010",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org",
      "snippet": "BMD results on DXA are reported as T-scores and Z scores (see the Box). The T-score should be reported in postmenopausal women and in men aged",
      "score": 0.5380859
    },
    {
      "number": 3,
      "title": "Osteoporosis",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-155-1-201107050-01001",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org",
      "snippet": "Laboratory Evaluation for Secondary Causes of Osteoporosis*. Essential tests. Comments/Disorder Detected. Complete blood count. Cancer. Serum calcium. High in",
      "score": 0.5114976
    },
    {
      "number": 4,
      "title": "Screening for Osteoporosis",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-153-2-201007200-00262",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org",
      "snippet": "by HD Nelson · 2010 · Cited by 275 — Dual-energy x-ray absorptiometry predicts fractures similarly for men and women; previous vertebral fractures with T-scores of J2.5 or less (82",
      "score": 0.43108177
    },
    {
      "number": 5,
      "title": "How Would You Manage This Patient With Osteoporosis?",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/10.7326/M18-0950",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org",
      "snippet": "Patients receiving treatment with alendronate who lose BMD should be evaluated for secondary causes of bone loss. Yield of laboratory testing to identify",
      "score": 0.40147716
    },
    {
      "number": 6,
      "title": "Development of a diverse osteoporosis screening tool for ...",
      "detail": "www.cell.com",
      "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(23)11014-0",
      "authors": "www.cell.com",
      "host": "www.cell.com",
      "snippet": "by MG Courtney · 2024 · Cited by 2 — The model provided high sensitivity for osteoporosis diagnosis, with consistently high results for those identifying as female, and across racial/ethnic groups.",
      "score": 0.2631475
    },
    {
      "number": 7,
      "title": "Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-024-73398-5",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Twenty-nine (58.0%) and 28 (56.0%) patients in the Deno and Romo groups, respectively, had a history of vertebral fractures. Regarding to the previous treatment history before this study, the number of treatment-naïve participants was 29 (58.0%) in the Deno group and 31 (62.0%) in the Romo group. Tw",
      "score": 0.5942929
    },
    {
      "number": 8,
      "title": "Evidence-Based Guideline for the management of ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41584-024-01094-9",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Statements addressed the appropriateness of using a reference database of women in the context of densitometric diagnosis of osteoporosis in men, using FRAX to assess fracture risk and in the setting of intervention thresholds (and whether these thresholds should be age-dependent), and the role of p",
      "score": 0.4845514
    },
    {
      "number": 9,
      "title": "Insights and implications of sexual dimorphism in osteoporosis | Bone Research",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41413-023-00306-4",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Taken together, anabolic medications, such as teriparatide, abaloparatide, and romosozumab, have shown greater therapeutic effects in randomized clinical trials on reducing clinical fracture risks in postmenopausal women with osteoporosis and at very high risk of fracture in comparison with patients",
      "score": 0.48016238
    },
    {
      "number": 10,
      "title": "Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-023-37944-x",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Reports related to common anti-osteoporosis drugs, including each bisphosphonate, denosumab, raloxifene, teriparatide, abaloparatide, and romosozumab, were queried and retrieved. And the generic and brand names of drugs were mapped based on the Drugs@FDA database () and DrugBank Online Database ().2",
      "score": 0.37676126
    },
    {
      "number": 11,
      "title": "Management of Postmenopausal Osteoporosis",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000004730~management-of-postmenopausal-osteoporosis-acog-clinical",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "### RECOMMENDATIONS:\n\nThis Clinical Practice Guideline includes updated recommendations on who should receive osteoporosis pharmacotherapy, the benefits and risks of available pharmacotherapy options, treatment monitoring and follow-up, and the role of calcium and vitamin D in the management of post",
      "score": 0.69399214
    },
    {
      "number": 12,
      "title": "Management of Osteoporosis and Low Bone Mass in Kidney ...",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cjasn/fulltext/10.2215/cjn.0000001149~management-of-osteoporosis-and-low-bone-mass-in-kidney",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Chronic kidney disease (CKD) increases the risk of fractures and death after fractures, due to CKD-associated osteoporosis driven by both age-related bone loss and CKD-specific disturbances in mineral metabolism. Bone health in CKD is evaluated with dual-energy X-ray absorptiometry, serum calcium, p",
      "score": 0.5172057
    },
    {
      "number": 13,
      "title": "Postmenopausal osteoporosis",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/menopausejournal/_layouts/15/oaks.journals/downloadpdf.aspx?an=",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "by MR McClung · 2025 · Cited by 4 — There is no limit to the duration of denosumab therapy. However, if treatment is stopped, follow-on therapy with a bisphosphonate is necessary to prevent",
      "score": 0.5151571
    },
    {
      "number": 14,
      "title": "Medical Management of Osteoporosis: Updates and Future ...",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/isoj/_layouts/15/oaks.journals/downloadpdf.aspx?an=",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "romosozumab, are the anabolic agents that improve bone density, increase bone strength, and prevent fractures.",
      "score": 0.4436251
    },
    {
      "number": 15,
      "title": "A Review of the Evidence and Suggested Guidelines for Its Use",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/edrv/article/26/5/688/2355192",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by AB Hodsman · 2005 · Cited by 958 — Reduction of vertebral fracture risk in post menopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial.",
      "score": 0.65861565
    },
    {
      "number": 16,
      "title": "The Challenges and Opportunities of ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jbmrplus/article-pdf/2/4/187/55120648/jbm410051.pdf",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by D Alarkawi · 2018 · Cited by 11 — Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral",
      "score": 0.5052006
    },
    {
      "number": 17,
      "title": "ACTIVExtend: 24 Months of Alendronate After 18 Months of ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jcem/article/103/8/2949/5001732",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by HG Bone · 2018 · Cited by 230 — Sequential ABL followed by ALN appears to be an effective treatment option for postmenopausal women at risk for osteoporosis-related fractures.",
      "score": 0.4977301
    },
    {
      "number": 18,
      "title": "Denosumab After Teriparatide in Premenopausal Women ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jcem/article-pdf/107/4/e1528/43775497/dgab850.pdf",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by E Shane · 2022 · Cited by 49 — Conclusion: These data support the use of sequential teriparatide and denosumab to increase BMD in premenopausal women with severe osteoporosis. Key Words:",
      "score": 0.41705835
    },
    {
      "number": 19,
      "title": "Clinician’s Guide to Prevention and Treatment of Osteoporosis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4176573",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "### US FDA-approved drugs for osteoporosis\n\nCurrent FDA-approved pharmacologic options for the prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, alendronate plus D, ibandronate, risedronate and zoledronic acid), calcitonin, estro",
      "score": 0.85216236
    },
    {
      "number": 20,
      "title": "The clinician's guide to prevention and treatment of osteoporosis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9546973",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Consider initiating pharmacologic treatment in postmenopausal women and men ≥ 50 years of age who have the following: Primary fracture prevention: T-score ≤ − 2.5 at the femoral neck, total hip, lumbar spine, 33% radius (some uncertainty with existing data) by DXA.Low bone mass (osteopenia: T-score ",
      "score": 0.8386933
    },
    {
      "number": 21,
      "title": "Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10885682",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "### Recommendation 1a:\n\nACP recommends that clinicians use bisphosphonates for initial pharmacologic treatment to reduce the risk of fractures in postmenopausal females diagnosed with primary osteoporosis (strong recommendation; high-certainty evidence).\n\n### Recommendation 1b:\n\nACP suggests that cl",
      "score": 0.8170061
    },
    {
      "number": 22,
      "title": "A Review of Various Clinical Practice Guidelines on Osteoporosis in the Last 5 Years",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10721745",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "3.   If intolerant to oral biphosphonates then Denosumab or IV biphosphonates are the best alternatives.\n\n#### Fig. 6.\n\nImage 29: Fig. 6\n\nOpen in a new tab\n\nPharmacological Agents used in Osteoporosis\n\nFor pharmacological interventions in postmenopausal osteoporosis, biphosphonates are recommended f",
      "score": 0.79580134
    },
    {
      "number": 23,
      "title": "Additional Background and Contextual Questions 2, 3, and 4 - Screening for Osteoporosis to Prevent Fractures: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK611362",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "| American College of Physicians, 2023318 | Postmenopausal women  Men | Screening: No specific guideline related to screening  Treatment   Bisphosphonates for initial pharmacologic treatment in postmenopausal females (high certainty) and males (low certainty) diagnosed with primary osteoporosis  Den",
      "score": 0.77873385
    },
    {
      "number": 24,
      "title": "Appendix A Table 4, Recommendations for Fracture or Osteoporosis Screening by Organization - Screening for Osteoporosis to Prevent Fractures: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK611362/table/appa.tab4",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "| American College of Physicians, 2023318 | Postmenopausal women  Men | Screening: No specific guideline related to screening  Treatment   Bisphosphonates for initial pharmacologic treatment in postmenopausal females (high certainty) and males (low certainty) diagnosed with primary osteoporosis  Den",
      "score": 0.76847315
    }
  ],
  "publishedAt": "2026-08-24T18:11:48.171124+00:00",
  "updatedAt": "2026-08-24T18:11:48.171124+00:00",
  "readingMinutes": 4,
  "slug": "osteoporosis-in-females"
}